Belantamab Mafodotin vs Pembrolizumab

Belantamab Mafodotin vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Belantamab Mafodotin and Pembrolizumab.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days.

Chemical Properties

Type: Belantamab Mafodotin — Antibody drug conjugate; Pembrolizumab — Antibody.